QIAGEN powered by

Are we becoming less confident in our NGS test interpretations?

New study suggests molecular diagnostics labs are at a crossroads

In a 2020 benchmarking study conducted as a partnership between a third-party news organization and QIAGEN, 69 molecular diagnostic labs performing genomic profiling were asked to self-assess their current variant interpretation and reporting capabilities for oncology applications. Survey questions focused on three core topics: test turnaround times, therapeutic recommendations, and overall reporting confidence.

Find out more about QIAGEN Clinical Insights for Oncology here.